Grifols, (NASDAQ: GRFS) and Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitabiliy, earnings, risk, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Grifols, and Tetralogic Pharmaceuticals Corp, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Grifols, 1 1 2 0 2.25
Tetralogic Pharmaceuticals Corp 0 0 0 0 N/A

Dividends

Grifols, pays an annual dividend of $0.28 per share and has a dividend yield of 1.3%. Tetralogic Pharmaceuticals Corp does not pay a dividend. Grifols, pays out 30.8% of its earnings in the form of a dividend.

Earnings and Valuation

This table compares Grifols, and Tetralogic Pharmaceuticals Corp’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Grifols, $4.63 billion 6.12 $1.28 billion $0.91 23.22
Tetralogic Pharmaceuticals Corp N/A N/A -$21.14 million ($1.76) -0.02

Grifols, has higher revenue and earnings than Tetralogic Pharmaceuticals Corp. Tetralogic Pharmaceuticals Corp is trading at a lower price-to-earnings ratio than Grifols,, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Grifols, and Tetralogic Pharmaceuticals Corp’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Grifols, 13.36% 17.87% 6.52%
Tetralogic Pharmaceuticals Corp N/A N/A -73.81%

Volatility and Risk

Grifols, has a beta of 0.98, suggesting that its stock price is 2% less volatile than the S&P 500. Comparatively, Tetralogic Pharmaceuticals Corp has a beta of 3, suggesting that its stock price is 200% more volatile than the S&P 500.

Institutional and Insider Ownership

22.1% of Grifols, shares are held by institutional investors. Comparatively, 2.7% of Tetralogic Pharmaceuticals Corp shares are held by institutional investors. 24.0% of Tetralogic Pharmaceuticals Corp shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Grifols, beats Tetralogic Pharmaceuticals Corp on 9 of the 12 factors compared between the two stocks.

About Tetralogic Pharmaceuticals Corp

TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company’s histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.

Receive News & Ratings for Grifols S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols S.A. and related companies with MarketBeat.com's FREE daily email newsletter.